Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 15,000 shares of the stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $6.37, for a total value of $95,550.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Clay Thorp also recently made the following trade(s):

  • On Thursday, December 7th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $6.13, for a total value of $30,650.00.
  • On Tuesday, November 14th, Clay Thorp sold 15,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.02, for a total value of $105,300.00.
  • On Thursday, November 16th, Clay Thorp sold 35,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.00, for a total value of $245,000.00.
  • On Thursday, October 5th, Clay Thorp sold 35,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $8.57, for a total value of $299,950.00.
  • On Thursday, September 14th, Clay Thorp sold 6,000 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $45,120.00.
  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.49, for a total value of $63,665.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The stock was sold at an average price of $7.52, for a total value of $184,240.00.

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) traded up $0.23 during midday trading on Thursday, reaching $6.20. The company’s stock had a trading volume of 202,820 shares, compared to its average volume of 152,443. Clearside Biomedical, Inc. has a 1 year low of $5.44 and a 1 year high of $14.14. The company has a current ratio of 4.57, a quick ratio of 4.57 and a debt-to-equity ratio of 0.15.

Clearside Biomedical (NASDAQ:CLSD) last issued its earnings results on Wednesday, November 8th. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.17). Clearside Biomedical had a negative return on equity of 90.72% and a negative net margin of 17,684.07%. The company had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.01 million. sell-side analysts anticipate that Clearside Biomedical, Inc. will post -2.33 EPS for the current fiscal year.

CLSD has been the topic of several research analyst reports. ValuEngine cut Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Zacks Investment Research cut Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. TheStreet cut Clearside Biomedical from a “c-” rating to a “d” rating in a research note on Friday, August 11th. Finally, Cowen restated a “buy” rating on shares of Clearside Biomedical in a research note on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $18.33.

A number of hedge funds and other institutional investors have recently modified their holdings of CLSD. State Street Corp increased its position in Clearside Biomedical by 99.7% in the second quarter. State Street Corp now owns 259,599 shares of the company’s stock worth $2,367,000 after buying an additional 129,621 shares during the period. Northern Trust Corp increased its holdings in shares of Clearside Biomedical by 94.8% during the second quarter. Northern Trust Corp now owns 221,468 shares of the company’s stock valued at $2,018,000 after purchasing an additional 107,754 shares during the period. FMR LLC increased its holdings in shares of Clearside Biomedical by 10.4% during the second quarter. FMR LLC now owns 981,292 shares of the company’s stock valued at $8,940,000 after purchasing an additional 92,192 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Clearside Biomedical during the first quarter valued at $604,000. Finally, Vanguard Group Inc. increased its holdings in shares of Clearside Biomedical by 11.2% during the second quarter. Vanguard Group Inc. now owns 701,550 shares of the company’s stock valued at $6,391,000 after purchasing an additional 70,488 shares during the period. 51.73% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Clearside Biomedical, Inc. (CLSD) Director Sells $95,550.00 in Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/07/clearside-biomedical-inc-clsd-director-sells-95550-00-in-stock.html.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.